10005: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

10015: A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid Hemangioendothelioma

10056: A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma

10330: A Phase II Study of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

* 10398: A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Chondrosarcoma and Clear Cell Sarcoma

▼* 10387: Pilot Trial of Nivolumab Plus Cabozantinib for Advanced Solid Tumors in Patients with HIV Infection (Dose-Escalation: advanced solid tumors in patients with HIV infection; Expansion)

Sarcoma

Alveolar soft part sarcoma

Unresectable or metastatic epithelioid hemangioendothelioma

Potentially resectable: liposarcoma, leiomyosarcoma, or undifferentiated pleomorphic sarcoma (UPS)/malignant fibrous histiosarcoma (MFH)

Chondrosarcoma

Histology-confirmed EWSR1 translocation-positive clear cell sarcoma or conventional or dedifferentiated chondrosarcoma

Kaposi’s sarcoma

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: June 15, 2020